Home › Research › Treatments
The antipsychotic discontinuation in Alzheimer disease trial: clinical rationale and study design
Devanand DP, Mintzer J, Schultz S, Sultzer D, de la Pena D, Gupta S, Colon S, Schimming C et al.. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2012-04-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
This study will provide clinically relevant data on the likelihood and time to relapse, and predictors of relapse, in patients switched from risperidone to placebo after response to risperidone treatment. Given the warnings about antipsychotic use in patients with dementia, studies of this type are essential to determine the optimal duration of treatment that confers the greatest benefit to risk ratio and to improve evidence-based treatment strategies.
What this study adds
Evidence grade: High
This is a trial. This paper describes the design of a trial on discontinuing the antipsychotic risperidone in patients with Alzheimer disease who responded to it. It aims to provide data on relapse likelihood and timing, not on treating, curing, or preventing Alzheimer's disease itself.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Devanand, D. P., Mintzer, J., Schultz, S., Sultzer, D., de la Pena, D., Gupta, S., et al. (2012). The antipsychotic discontinuation in Alzheimer disease trial: clinical rationale and study design. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. https://doi.org/10.1097/jgp.0b013e3182110563
Vancouver
Devanand DP, Mintzer J, Schultz S, Sultzer D, de la Pena D, Gupta S, et al. The antipsychotic discontinuation in Alzheimer disease trial: clinical rationale and study design. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. 2012. doi:10.1097/jgp.0b013e3182110563. PMID: 21407047.
BibTeX
@article{devanand2012-21407047,
author = {Devanand, D. P. and Mintzer, J. and Schultz, S. and Sultzer, D. and de la Pena, D. and Gupta, S. and Colon, S. and Schimming, C. and others},
title = {{The antipsychotic discontinuation in Alzheimer disease trial: clinical rationale and study design}},
journal = {The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry},
year = {2012},
doi = {10.1097/jgp.0b013e3182110563},
pmid = {21407047},
url = {https://doi.org/10.1097/jgp.0b013e3182110563}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- This study will provide clinically relevant data on the likelihood and time to relapse, and predictors of relapse, in patients switched from risperidone to placebo after response to risperidone treatment.
- Given the warnings about antipsychotic use in patients with dementia, studies of this type are essential to determine the optimal duration of treatment that confers the greatest benefit to risk ratio and to improve evidence-based treatment strategies.
Why it matters
This paper describes the design of a trial on discontinuing the antipsychotic risperidone in patients with Alzheimer disease who responded to it. It aims to provide data on relapse likelihood and timing, not on treating, curing, or preventing Alzheimer's disease itself.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthHigh
How this study scored 56/100
Published in a peer-reviewed journal, and it is a randomized controlled trial. Scored zero for sample size and effect reported because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry) |
| Journal's citation record | 2 / 4 | American Journal of Geriatric Psychiatry: journal h-index 178 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2012 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (pubmed indexes it as a clinical or observational study) |
| Randomized / blinded | 1 / 2 | Randomized (as stated in the record) |
| Times cited | 3 / 7 | Cited 18 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.1 citations a year over 16 year(s) since 2012 |
| Impact for its field and year | 2 / 6 | Cited 1.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Bruce Lubotsky Levin: h-index 53 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of California, Los Angeles: institution h-index 1,923 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 10 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 21407047) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 56 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1097/jgp.0b013e3182110563
- PubMed: 21407047
- Original source →
- Free full text: PubMed Central →
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.